Company

NiKang Therapeutics, Inc.

NiKang Therapeutics develops small molecule drugs for oncology targets.

About

Founded in 2017 and based in Wilmington, NiKang Therapeutics develops small molecule drug candidates for cancer treatment. Its pipeline includes candidates targeting SHP2, HIF2a, and CDK2. On May 19, 2021, it raised USD 200 mn in Series C funding.

3Funding rounds

18Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in